Compare AstraZeneca plc (AZN) vs Global X Robo Global Robotics & Automation ETF (ROBO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Global X Robo Global Robotics & Automation ETF — how do they compare? AstraZeneca plc trades at $158.62 (market cap $248.14B), while Global X Robo Global Robotics & Automation ETF trades at $84.75. The key difference: AstraZeneca plc pays a 2.01% dividend while Global X Robo Global Robotics & Automation ETF pays none, and Global X Robo Global Robotics & Automation ETF is trading nearer its 52-week high, AstraZeneca plc nearer its low. Which is the better fit depends on your goals.
| AZN | ROBO | |
|---|---|---|
Market Cap | $248.14B | — |
Sector | Health | Sector/Thematic |
52-Week High | $209.48 | $90.34 |
52-Week Low | $147.06 | $62.34 |
Enterprise Value | $275.41B | — |
Dividend Yield | 2.01% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $157.39, down 2.79% amid bearish technical signals and merger speculation. The company demonstrates strong fundamentals with revenue growth to $58.74B in 2025 and a net income margin of 17.02%. Recent earnings have consistently beaten estimates, and analyst consensus is positive with 47.5% buy ratings. However, news of potential merger talks with Bristol Myers Squibb and a related legal investigation have introduced volatility.
The outlook is mixed; solid profitability and growth support long-term value, but near-term price pressure from technical indicators and merger uncertainty presents a cautious entry point. Key risks include deal execution challenges and integration complexities should a merger proceed.
ROBO Global Robotics and Automation Index ETF (ROBO) trades at $84.79, up 1.59% with strong bullish technical signals from moving averages. The robotics ETF benefits from AI infrastructure expansion and recent sector momentum, though key valuation metrics remain undisclosed. Recent news highlights robotics as the next phase of AI investment beyond semiconductors, with thematic ETF comparisons favoring ROBO's diversified approach to automation exposure.
Outlook remains positive given structural AI adoption tailwinds, but elevated RSI levels suggest near-term consolidation risk. The ETF's 79-stock global portfolio offers diversified robotics exposure, though cyclical industrial dependencies and valuation concerns after recent rallies present balanced risk-reward dynamics for long-term investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Global X Robo Global Robotics & Automation ETF
ROBO is a thematic ETF that tracks the global robotics and automation industry. It provides diversified exposure to companies leading in industrial robotics, 3D printing, and surgical systems, with holdings like Intuitive Surgical and Zebra Technologies.
Read more on ROBO →
